THE INFLUENCE OF BODY MASS INDEX ON THE PROGNOSIS OF PATIENTS WITH COPD: THE EFFECT OF METABOLIC SYNDROME AND THE VALIDITY OF THE OBESITY PARADOX

Authors

  • Elena-Andreea MOALEȘ ‟Grigore Popa” University of Medicine and Pharmacy Iași
  • Lucia Corina DIMA-COZMA ‟Grigore Popa” University of Medicine and Pharmacy Iași
  • Clementina COJOCARU ‟Grigore Popa” University of Medicine and Pharmacy Iași
  • A. MIHORDEA Clinical Rehabilitation Hospital, Iasi, Romania
  • H. MACOVEI Clinical Rehabilitation Hospital, Iasi, Romania
  • R. S. COZMA ‟Grigore Popa” University of Medicine and Pharmacy Iași
  • Maria Magdalena LEON ‟Grigore Popa” University of Medicine and Pharmacy Iași
  • F. MITU

DOI:

https://doi.org/10.22551/g7jv5d27

Abstract

Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a complex systemic disease rather than a condition limited to the lungs. Malnutrition, cachexia, and obesity contribute to decreased exercise capacity, higher rates of exacerbations and increased mortality. The aim of the study was to investigate the influence of the body mass index (BMI) on the prognosis of patients diagnosed with COPD, in the presence or absence of MetS. Materials and methods: A total of 100 patients with a confirmed diagnosis of COPD were enrolled in the study, of whom 65 patients met the diagnostic criteria for MetS. Patients were evaluated based on clinical, anthropometric, and laboratory parameters. BMI was calculated for each patient, and its association with disease prognosis was subsequently analyses, considering the presence or absence of MetS. Results: The patients were divided into two groups based on the presence or absence of metabolic syndrome. Both BMI and waist circumference showed statistically significant differences between groups (p<0.001). Plasma glucose levels were significantly higher in COPD patients with MetS and BMI≥ 25 kg/m2 compared to those without MetS (p= 0.020). Plasma triglyceride levels were also significantly higher in the same group (p= 0.034). No statistically significant differences were observed for systolic and diastolic blood pressure across the groups (p> 0.05). Conclusions: Continuous monitoring of BMI and the prevention of cachexia are essential strategies for reducing mortality rates, whereas the prevention of obesity contributes to the reduction of cardiovascular complications.

Author Biographies

  • Elena-Andreea MOALEȘ, ‟Grigore Popa” University of Medicine and Pharmacy Iași

    Faculty of Medicine
    Department of Medical Specialties (I)
    Elytis Hospital, Iasi, Romania

  • Lucia Corina DIMA-COZMA, ‟Grigore Popa” University of Medicine and Pharmacy Iași

    Faculty of Medicine
    Department of Medical Specialties (I)
    Clinical Rehabilitation Hospital, Iasi, Romania

  • Clementina COJOCARU, ‟Grigore Popa” University of Medicine and Pharmacy Iași

    Faculty of Medicine
    Department of Medical Specialties (I)
    Clinical Rehabilitation Hospital, Iasi, Romania

  • R. S. COZMA, ‟Grigore Popa” University of Medicine and Pharmacy Iași

    Faculty of Medicine
    Department of Surgery (II)
    Clinical Rehabilitation Hospital, Iasi, Romania

  • Maria Magdalena LEON, ‟Grigore Popa” University of Medicine and Pharmacy Iași

    Faculty of Medicine
    Department of Medical Specialties (I)
    Clinical Rehabilitation Hospital, Iasi, Romania

  • F. MITU

    Faculty of Medicine
    Department of Medical Specialties (I)
    Clinical Rehabilitation Hospital, Iasi, Romania
    Romanian Academy of Medical Sciences, Bucharest, Romania
    Romanian Academy of Scientists, Bucharest, Romania

References

1. Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018; 198(9): 1130-1139.

2. Sandelowsky H, Weinreich UM, Aarli BB, et al. COPD - do the right thing. BMC Fam Pract 2021; 22(1): 244.

3. Jiang Q, Ma Z, Sun J, Li Y. Association of dietary inflammatory indices with sarcopenia and all-cause mortality in COPD patients. Front Nutr 2024; 11: 1395170.

4. Machado FVC, Vogelmeier CF, Jörres RA, et al. Differential impact of low fat-free mass in people with COPD based on BMI classifications: results from the COPD and systemic consequences- comorbidities network. Chest 2023; 163(5): 1071-1083.

5. Hanson C, Rutten EP, Wouters EF, Rennard S. Influence of diet and obesity on COPD development and outcomes. Int J Chron Obstruct Pulmon Dis 2014; 9: 723-733.

6. Sabino PG, Silva BM, Brunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics (Sao Paulo) 2010; 65(6): 599-605.

7. Fekete M, Szollosi G, Tarantini S, et al. Metabolic syndrome in patients with COPD: Causes and pathophysiological consequences. Physiol Int 2022; 109(1): 90-105.

8. Fekete M, Szarvas Z, Fazekas-Pongor V, Lehoczki A, Tarantini S, Varga JT. Effects of omega-3 supplementation on quality of life, nutritional status, inflammatory parameters, lipid profile, exercise tolerance and inhaled medications in chronic obstructive pulmonary disease. Ann Palliat Med 2022; 11(9): 2819-2829.

9. Beaumont M, Forget P, Couturaud F, Reychler G. Effects of inspiratory muscle training in COPD patients: A systematic review and meta-analysis. Clin Respir J 2018; 12(7): 2178-2188.

10. Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther 2019; 198: 160-188.

11. James BD, Jones AV, Trethewey RE, Evans RA. Obesity and metabolic syndrome in COPD: Is exercise the answer? Chron Respir Dis 2018; 15(2): 173-181.

12. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(6): 809-813.

13. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study. Thorax 2006; 61(9): 772-778.

14. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107(9): 1376-1384.

15. Eckel RH, Grundy SM and Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-1428.

16. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7): 728-735.

17. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: Impact, measurement and mechanisms. Respirology 2015; 20(8): 1160-1171.

18. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022; 10(5): 447-458.

19. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol 2020; 33: 101544.

20. Palma G, Sorice GP, Genchi VA, et al. Adipose tissue inflammation and pulmonary dysfunction in obesity. Int J Mol Sci 2022; 23(13): 7349.

21. Suh YJ, McDonald MN, Washko GR, et al. Lung, fat and bone: increased adiponectin associates with the combination of smoking-related lung disease and osteoporosis. Chronic Obstr Pulm Dis 2018; 5(2): 134-143.

22. Mariniello DF, D'Agnano V, Cennamo D, et al. Comorbidities in COPD: current and future treatment challenges. J Clin Med 2024; 13(3): 743.

23. Kim T, Shin SH, Kim H, Im Y, Cho J, Kang D, Park HY. Longitudinal BMI change and outcomes in Chronic Obstructive Pulmonary Disease: a nationwide population-based cohort study. Respir Res 2024; 25(1): 150.

24. Perrot L, Greil A, Boirie Y, et al. Prevalence of sarcopenia and malnutrition during acute exacerbation of COPD and after 6 months recovery. Eur J Clin Nutr 2020; 74(11): 1556-1564.

25. Zhou J, Liu Y, Yang F, et al. Risk factors of sarcopenia in COPD patients: a meta-analysis. Int J Chron Obstruct Pulmon Dis 2024; 19: 1613-1622.

26. Guo C, Yu T, Chang LY, Bo Y, et al. Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: a 21-year longitudinal cohort study. Respir Med 2021; 184: 106471.

27. Smulders L, van der Aalst A, Neuhaus EDET, et al. Decreased risk of COPD exacerbations in obese patients. COPD 2020; 17(5): 485-491.

28. Lennon H, Sperrin M, Badrick E, Renehan AG. The obesity paradox in cancer: a review. Curr Oncol Rep 2016; 18: 56.

29. Sun Y, Milne S, Jaw JE, et al. BMI is associated with FEV(1) decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res 2019; 20: 236.

30. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS ONE 2012; 7: e43892.

31. Divo MJ, Cabrera C, Casanova C, et al. Comorbidity distribution, clinical expression and survival in COPD patients with different body mass index. J COPD F 2014; 1(2): 229-238.

32. Yao S, Zeng L, Wang F, Chen K. Obesity paradox in lung diseases: what explains it? Obes Facts 2023; 16(5): 411-426.

33. Yamaya M, Usami O, Nakayama S, et al. Malnutrition, airflow limitation and severe emphysema are risks for exacerbation of chronic obstructive pulmonary disease in Japanese subjects: a retrospective single-center study. Int J Chron Obstruct Pulmon Dis 2020; 15: 857-868.

34. Chiappetta S, Schaack HM, Wölnerhannsen B, Stier C, Squillante S, Weiner RA. The impact of obesity and metabolic surgery on chronic inflammation. Obes Surg 2018; 28(10): 3041-3043.

Additional Files

Published

2025-07-08

Issue

Vol. 129 No. 2 (2025): The Medical-Surgical Journal

Section

INTERNAL MEDICINE - PEDIATRICS

License

Copyright (c) 2025 The Medical-Surgical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form